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Abstract
Background—Guidelines now recommend that adolescents routinely receive human
papillomavirus (HPV) vaccine. Because little is known about uptake among boys, we assessed
HPV vaccine initiation in a population-based sample of adolescent boys and girls.
Methods—We analyzed weighted data from 751 parents who reported on an 11- to 17-year-old
son or daughter for the 2010 North Carolina Child Health Assessment and Monitoring Program
survey. Stratified multivariate logistic regression analyses identified correlates of HPV vaccine
initiation separately for boys and girls.
Results—Only 14% of sons had received one or more doses of HPV vaccine compared to 44%
of daughters (p<0.01). For both sons and daughters, vaccine initiation correlated with age and
having received meningococcal vaccine. Among sons, initiation of HPV vaccine was lower for
those living in high income households (odds ratio [OR]=0.22, 95% CI, 0.09–0.53) and higher for
those whose race was neither white nor black (OR=3.26, 95% CI, 1.06–10.04). When asked to
give the main reason for not vaccinating their child against HPV, parents of unvaccinated sons
were more likely than those of daughters to report not getting a provider’s recommendation or not
being aware the vaccine was available for their child, but less likely to report concern about safety
(p<0.01). At least 86% of unvaccinated children had missed an opportunity to receive HPV
vaccine.
Conclusions—HPV vaccine correlates and concerns varied for parents of boys and girls. To
improve very low levels of uptake among boys, providers should recommend HPV vaccine
concomitant with other adolescent vaccines.
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Since 2006 the Centers for Disease Control and Prevention (CDC) has recommended
routinely providing human papillomavirus (HPV) vaccine to adolescent females as a
strategy for preventing genital warts and several types of cancer [1]. In October 2011, the
agency extended this recommendation to cover adolescent males, thereby strengthening the
previous “permissive recommendation” the vaccine received when first approved for this
population in 2009 [2]. The more recent guidelines call for routine vaccination of 11- to 12-
year-old boys, with 9- to 21-year-old males considered age-eligible [2]. Guidelines for
females are similar, but extend to 26 years of age [1].
Achieving widespread HPV vaccination among males will require surveillance to track
coverage and identify modifiable correlates of uptake. Although a small body of existing
research characterizes knowledge and attitudes related to HPV vaccination among males [3–
10], less is currently known about uptake in this population. Using national samples, two
studies conducted in 2010 found that, in the first year after licensure, only 1–2% of
adolescent boys had received at least one dose of HPV vaccine [11–12]. Existing research
identifies correlates of HPV vaccine uptake among females [13–17], but to our knowledge,
no published studies address this question for adolescent males. Because factors such as
perceived benefit of HPV vaccine differ by child’s sex [4], we cannot assume that correlates
of uptake among boys will mirror those of girls.
To address gaps in the literature, we used data from a statewide survey to: (a) characterize
HPV vaccine initiation among adolescent males and females using a population-based
sample; (b) assess missed opportunities for providing HPV vaccine; and (c) assess the main
reason parents reported for not getting their child HPV vaccine. By investigating how HPV
vaccination differs by child’s sex, this study aims to inform the development of targeted




We used data from two state-based telephone surveys conducted in North Carolina in 2010:
the Behavioral Risk Factor Surveillance System (BRFSS) survey and the Child Health
Assessment and Monitoring Program (CHAMP) survey. North Carolina BRFSS is an annual
population-based survey of adults contacted through random-digit dialing [18]. If a 2010
BRFSS respondent reported living in a household with a child under 18 years of age, that
household became eligible for CHAMP, a follow-up survey offered in English and Spanish
[19]. The adult caregiver identified as being most knowledgeable about the child’s health
completed CHAMP. For households with multiple children, survey software randomly
selected an index child to be the focus of the survey. Unique identifiers linked data from
BRFSS respondents and CHAMP caregivers at the household level. Because most
caregivers (87%) reported being the biological parent of the index child, we refer to
CHAMP respondents as “parents.”
The response rate for the 2010 North Carolina BRFSS survey was 61% of 20,208 eligible
households as estimated by the Council of American Research Organization (CASRO)
response rate calculation [20]. Of the 3,174 BRFSS parents asked to participate in CHAMP,
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2,009 (63%) completed the survey. Because guidelines recommend HPV vaccination for 11-
to 12-year-olds with older adolescents eligible for “catch up” immunization, we focused this
study on children ages 11 through 17. We excluded data from 1,258 (63%) parents,
including: those whose index child was not age 11–17 years (n=1,057); those who had not
heard of HPV vaccine (n=152); and those who were unsure whether their child had received
HPV vaccine or who declined to answer (n=49) (Figure 1). Our analytic sample consisted of
the remaining 751 parents, of whom 359 (48%) reported on a male index child and 392
(52%) reported on a female index child. Overall, 20 parents completed the survey in
Spanish. The University of North Carolina Institutional Review Board determined that this
analysis was exempt from review.
Measures
The CHAMP survey assessed HPV vaccine initiation with a single item: “Has (CHILD’S
NAME) had any shots of the HPV vaccine?” Interviewers asked parents of unvaccinated
adolescents to identify the main reason the child had not been vaccinated against HPV.
CHAMP also assessed other healthcare-related variables, including whether the child had:
health insurance coverage; a regular healthcare provider; a preventive care visit in the
previous year; or ever received meningitis vaccine or a tetanus shot. The survey also
assessed the child’s sex, age, race, and school type as well as the highest level of education
attained by anyone in the household and sex of the parent completing the interview.
The BRFSS survey assessed additional parent information, including age, employment
status, and receipt of seasonal flu vaccine (shot or nasal spray) in the previous year. BRFSS
respondents also indicated household income and the total number of children living in the
household. We defined households located within a metropolitan statistical area (MSA) as
“urban” and those outside an MSA as “rural” [21].
Statistical Analyses
We used logistic regression to identify bivariate correlates of HPV vaccine initiation for
male and female adolescents separately. We then entered statistically significant (p<0.05)
correlates into multivariate models. To assess “missed opportunities” for receiving HPV
vaccine, we calculated the percentage of unvaccinated boys (n=316) and girls (n=218) who
had received a recent preventive care visit or meningococcal vaccine. We used Pearson’s
chi-squared tests to compare parents’ main reason for not getting their children vaccinated
against HPV, analyzing reasons separately for sons (n=314) and daughters (n=215); these
analyses excluded 5 parents who did not give a reason. We analyzed data using Stata
Version 12.0 (Statacorp, College Station, TX), incorporating sample weights to account for
the study design. We report unweighted frequencies and weighted proportions, odds ratios,
and confidence intervals. All statistical tests were 2-tailed with a critical alpha of 0.05.
RESULTS
Sample Characteristics
Sons and daughters did not differ on any of the thirteen sample characteristics assessed
(Table 1). The mean age for sons and daughters was 14.0 years. Most parents reported on
children who were non-Hispanic white (69%) or black (20%), and we collapsed the
remaining racial/ethnic designations into a third category of “other” (12%), which included
children parents identified as Hispanic or Latino (n=48), American Indian or Alaska Native
(n=14), Asian (n=5), multiracial (n=4), or some other race (n=11). The majority of parents
indicated that their child attended public school (90%), was covered by some form of health
insurance (95%), had a regular healthcare provider (82%), and had received a preventive
check-up in the last year (83%).
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Parents’ mean age was 44 years. Most parents were female (88%) and employed (69%), and
about half reported an annual household income of $50,000 or more (54%). Most
households included more than one child (70%), as well as at least one family member with
some college education (81%). About three quarters of households (74%) were located in an
urban area.
HPV Vaccine Initiation
Just 14% of parents of sons reported their child had received one or more doses of HPV
vaccine compared to 44% of parents of daughters (p<0.01). In bivariate and multivariate
analyses (Tables 2 and 3), vaccine initiation among sons was correlated with child’s age and
race, household income, and the use of other vaccines. Vaccine initiation was higher for
boys who were older (13–15 years old vs. 11–12 years old) (multivariate odds ratio [OR] =
3.34, 95% CI, 1.16–9.67) and whose race was neither white nor black (OR = 3.26, 95% CI,
1.06–10.04), but initiation was lower for sons who lived in households with annual incomes
greater than $50,000 (OR = 0.22, 95% CI, 0.09–0.53). HPV vaccination was more common
among sons who had received meningococcal vaccine (OR = 7.98, 95% CI, 3.70–17.21) or
whose parents had received flu vaccine (2.47, 95% CI, 1.05–5.84). Although non-Hispanic
black race was also associated with HPV vaccine initiation in the bivariate analysis (OR =
4.71, 95% CI, 1.88–11.84), this relationship lost statistical significance in the multivariate
model (OR = 1.80, 95% CI, 0.76–4.30). Post-hoc mediation analysis suggested that all four
variables in the final model contributed to this reduction in the odds ratio for black race:
household income (31% reduction), boys’ use of meningococcal vaccine (27%), boys’ age
(26%), and parents’ use of flu vaccine (16%).
HPV vaccine initiation among daughters was correlated with child’s age, school type, and
meningococcal vaccination status, in bivariate and multivariate analyses (Tables 2 and 3).
Compared to 11–12 year olds, HPV vaccination was more common among 13–15 year olds
(OR = 2.21, 95% CI, 1.12–4.36) and 16–17 year olds (OR = 3.24, 95% CI, 1.52–6.91). HPV
vaccine initiation was lower among girls attending private or home school rather than public
school (OR = 0.30, 95% CI, 0.12–0.71), and higher among those who had received
meningococcal vaccine (OR = 2.36, 95% CI, 1.36–4.10).
Missed Opportunities
Among adolescents who had not initiated HPV vaccination, most had missed an opportunity
to receive vaccine. In the case of unvaccinated boys (n=316), 84% had received a preventive
care visit in the 12 months prior to the survey. Among the remaining 53 boys without a
recent visit, 16% had received meningococcal vaccine, indicating some prior engagement
with the healthcare system during adolescence. In the case of unvaccinated girls (n=218),
79% had received a recent preventive visit, and among the remaining 52 girls without a
recent visit, 25% had received meningococcal vaccine. In all, 87% of boys (n=276) and 84%
of girls (n=176) had missed the opportunity to receive HPV vaccine in the course of a recent
preventive visit or along with meningococcal vaccine.
Reasons for Not Getting HPV Vaccine
Parents of unvaccinated sons and daughters commonly reported one of 7 different reasons
for not getting their child HPV vaccine (Figure 2). Parents of sons were more likely than
those of daughters to indicate their main reason was not receiving a provider’s
recommendation (27% versus 14%) or being unaware that HPV vaccine was available for
their child’s sex (17% versus 0%) (p<0.01). Parents of daughters were more likely than
those of sons to report concerns about vaccine safety or side effects as their main reason
(19% versus 7%) (p<0.01).
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In this statewide sample of parents in North Carolina, we found that correlates and concerns
related to HPV vaccine initiation differed for boys and girls. With 14% of parents of sons
reporting initiation, this study suggests uptake among boys has increased in North Carolina
beyond previously reported national estimates [11,12], but is still very low. Initiation among
boys was linked to other vaccine use by the child and parent, and was also correlated with
boys’ demographic characteristics, such that sons from lower-income and minority (non-
white and non-black) backgrounds received HPV vaccine more often. This pattern of
initiation may be due to greater vaccine acceptability in these populations [4] or to increased
access to vaccines through Vaccines for Children (VFC), a program that provides vaccines
at no cost to uninsured, underinsured, and Medicaid-insured youth as well as to American
Indians and Alaska Natives [22].
Although both explanations are plausible, we suspect that North Carolina’s VFC program
played an especially important role in increasing HPV vaccine uptake among North Carolina
boys beyond national estimates. In 2010, approximately one-third of first doses of HPV
vaccine funded by the program were administered to boys (A. Dayton, personal
communication, July 3, 2012). Our hypothesis is also partially supported by our finding that
two variables we would expect to correspond to VFC participation, household income and
boys’ use of meningococcal vaccine, mediated much of the relationship between black race
and HPV vaccination. Whatever the mechanism, vaccine initiation among adolescents from
low-income and minority backgrounds is encouraging given that these populations are at
risk for experiencing cancer-related health disparities later in life [23].
With 44% of parents reporting their daughter received one or more doses of HPV vaccine,
this study’s estimate of initiation among girls is comparable to other state and national
estimates. For example, the 2010 National Immunization Survey (NIS)–Teen found that
about half (52%) of adolescent females in North Carolina had initiated HPV vaccine, a
figure close to the national average of 49% [12]. Unlike NIS-Teen, our study included 11- to
12-year-olds who were still in the target age range for routine vaccination. When we
excluded this younger group, our analysis placed initiation at 50%, in line with NIS–Teen
findings. Compared to sons, initiation among daughters was less strongly or consistently
associated with other vaccine use. Girls’ initiation was not directly correlated with
demographic characteristics, but did vary by school type with private- or home-schooled
girls less often receiving HPV vaccine. Furthermore, unlike an analysis of 2008 NC
CHAMP data [13], we did not find disparities in HPV vaccination related to healthcare
utilization or rural residence. This good news is tempered by our finding that girls’ overall
initiation level improved only modestly from 31% in 2008 [13].
Given that our findings are based on data collected in 2010 before the CDC issued
recommendations for routine vaccination of boys against HPV, the difference in coverage
we observed between sons and daughters in our sample is not surprising. However, the
differences we found in correlates of initiation by sex is unexpected. Age and other vaccine
use were correlates for both groups, but demographic characteristics related to lower income
and minority race were associated with HPV vaccine initiation for boys, but not girls. These
differences are even more pronounced when our correlates for boys are compared to early
correlates for girls. As previously mentioned, an analysis of 2008 NC CHAMP data found
that girls’ initiation of HPV vaccine two years post-licensure was characterized by health
disparities, and girls were less likely to get the vaccine if they lacked a regular healthcare
provider, had not had a recent preventive visit, lived in a rural county, or if the parent
responding to the questionnaire was unemployed [13]. In other words, while early HPV
Gilkey et al. Page 5













initiation among boys seems to have been more common among at-risk populations, the
opposite appears to have been true for girls.
These differences in who first adopts HPV vaccine suggest an interaction between sex and
other demographic characteristics that is likely related to the female-specific approach of
early HPV vaccination efforts. For example, it may be that socially-advantaged parents are
more influenced than others by practice recommendations and marketing efforts [24], which
extolled the benefits of HPV vaccination for girls soon after licensure, but which in 2010
had focused much less extensively on boys. Alternatively, concerns about HPV vaccine
safety may differ such that lower income and minority parents harbor safety concerns more
often for girls than for boys. Differential patterns of healthcare use by adolescents could also
contribute to differences in uptake since, compared to females, adolescent males seek
preventive care less often and in different venues, thereby decreasing the influence of having
a regular healthcare provider on HPV vaccination for boys [25,26].
The CDC’s new guidelines should raise awareness of HPV vaccination for boys among
healthcare providers and in the general public. In addition, the guidelines are likely to
increase boys’ access to HPV vaccine as private insurers typically cover the cost of vaccines
recommended for routine use [2]. Although these factors will no doubt improve uptake
among boys to some extent, the experience of girls suggests that attaining the widespread
coverage needed to achieve population-level protection will require a more concerted effort.
Toward this end, our findings have implications for practitioners as they seek to address
very low levels of vaccine initiation among boys. First, our findings underscore the
importance of healthcare provider recommendation of HPV vaccine (14–16,27). When
asked why they had not gotten HPV vaccine for their child, almost half (44%) of parents of
unvaccinated sons reported they were either unaware the vaccine was available for boys or
that their provider had not recommended it. Second, compared to daughters, HPV vaccine
initiation among sons was more closely linked to the use of other vaccines, suggesting that
providing HPV vaccine concomitant with other adolescent vaccines may be particularly
important in this population. Given that parents in our sample reported a high degree of
engagement with the healthcare system, providers are well positioned for meeting families’
informational needs and for integrating HPV vaccination into the processes of routine care.
Finally, we were interested to see that parents of sons less often reported concerns about
safety and side effects as their main reason for not getting their child vaccinated against
HPV. Because so many parents in our sample were unaware HPV vaccine was available for
boys, we cannot yet conclude that perceptions about vaccine safety will present less of a
barrier in the vaccination of boys. However, future studies should consider whether
perceived harms related to HPV vaccine differ by child’s sex.
This study has several strengths, including the use of a large population-based sample of
parents and the ability to conduct interviews with Spanish-speaking as well as English-
speaking parents. Limitations include the cross-sectional study design and parental report of
HPV vaccine initiation. However, parental recall of HPV vaccination may be more accurate
than recall for other types of vaccines [28]. The CHAMP survey did not assess some factors
that are important for HPV vaccination, such as anticipated regret, perceived risk of getting
HPV-related diseases, and perceived barriers to vaccination [14–15]. Additionally, parents
in our study were more educated than the state as a whole [29], and our sample was
restricted to respondents with a landline phone. For these reasons, our results may be
somewhat less generalizable to less educated, low-income, rural, and minority populations,
even after weighting [30].
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In North Carolina, HPV vaccine initiation levels among adolescent girls have consistently
mirrored the national average. This study provides preliminary information about the
prevalence and correlates of HPV vaccine initiation among boys, and tracking uptake in this
population will be important for evaluating the state’s success at meeting recommendations
for the routine vaccination of boys. Based on our statewide sample of parents, our findings
suggest that provider recommendation of HPV vaccine alongside other vaccines is a cancer
prevention strategy that may be particularly well suited for improving the very low level of
coverage among boys.
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We assessed HPV vaccine initiation in a population-based sample of adolescents.
Only 14% of boys had initiated HPV vaccine compared to 44% of girls.
For both sexes, initiation correlated with age and use of meningococcal vaccine.
For boys, initiation correlated with lower income and non-black/non-white race.
For girls, in was itiation associated with public school attendance.
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Main reason for not getting son or daughter HPV vaccine
*p < 0.01
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Table 1
Child, parent, and household characteristics for sons (n=359) and daughters (n=392).a
Sons Daughters
n (%) n (%)
Child characteristics
 Age (years)
  11–12 88 (28) 100 (29)
  13–15 160 (42) 172 (44)
  16–17 111 (30) 120 (27)
 Race
  Non-Hispanic white 261 (71) 289 (67)
  Non-Hispanic black 61 (19) 58 (20)
  Other 37 (10) 45 (13)
 School typeb
  Public 313 (89) 351 (90)
  Private/home schooled 43 (11) 41 (10)
 Health insurance coverage
  No/don’t know 20 (4) 27 (7)
  Yes 339 (96) 365 (93)
 Regular healthcare provider
  No/don’t know 67 (19) 65 (17)
  Yes 292 (81) 327 (83)
 Preventive check-up in the last year
  No/don’t know 55 (14) 75 (20)
  Yes 304 (86) 317 (80)
Parent characteristics
 Age (years)
  ≤ 39 94 (29) 88 (26)
  40–49 166 (47) 203 (52)
  ≥ 50 99 (24) 101 (22)
 Sex
  Female 312 (86) 346 (90)
  Male 47 (14) 46 (10)
 Employment status
  Employed for wages/self-employed 256 (70) 274 (68)
  Other (unemployed, homemaker, student, retired, unable to work) 103 (30) 118 (32)
Household characteristics
 Annual income
  < $50,000 132 (38) 136 (37)
  ≥ $50,000 200 (54) 216 (54)
  Not reported 27 (8) 40 (10)
 Highest education
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Sons Daughters
n (%) n (%)
  High school or less 59 (19) 70 (18)
  Some college or more 300 (81) 322 (82)
 Number of children
  1 164 (28) 183 (32)
  ≥ 2 195 (72) 209 (68)
 Urbanicity
  Rural 85 (28) 93 (24)
  Urban 274 (72) 299 (76)
a
Table shows raw frequencies and weighted percentages. Percentages may not total 100% due to rounding.
b
Excludes parents who indicated that they did not know their child’s school type (n=1 son), that their child was not in school (n=1 son), or who
refused to answer (n=1 son).
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